Holen Sie sich die Stockscreener-App
15.61
4.70%
-0.77
Schlusskurs vom Vortag:
$16.38
Offen:
$16.45
24-Stunden-Volumen:
3.78M
Relative Volume:
0.75
Marktkapitalisierung:
$12.45B
Einnahmen:
$220.00K
Nettoeinkommen (Verlust:
$-1.21B
KGV:
-9.7325
EPS:
-1.6039
Netto-Cashflow:
$-387.48M
1W Leistung:
-12.55%
1M Leistung:
+16.84%
6M Leistung:
-12.99%
1J Leistung:
-22.95%
1-Tages-Spanne:
$15.55
$16.58
1-Wochen-Bereich:
$15.55
$18.42
52-Wochen-Spanne:
$12.07
$29.23
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
15.61 | 12.45B | 220.00K | -1.21B | -387.48M | -1.6039 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-08 | Eingeleitet | Stifel | Buy |
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2025-12-17 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-17 | Eingeleitet | Barclays | Underweight |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Neutral |
| 2025-07-01 | Eingeleitet | UBS | Buy |
| 2025-06-11 | Eingeleitet | Leerink Partners | Underperform |
| 2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | Goldman | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-07 | Eingeleitet | Citigroup | Buy |
| 2024-03-26 | Eingeleitet | Stifel | Buy |
| 2018-06-28 | Herabstufung | Janney | Buy → Neutral |
| 2018-05-02 | Eingeleitet | Janney | Buy |
| 2018-04-12 | Bestätigt | Needham | Buy |
| 2018-02-13 | Eingeleitet | BTIG Research | Buy |
| 2018-01-04 | Eingeleitet | SunTrust | Buy |
| 2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-05 | Bestätigt | Needham | Buy |
| 2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-30 | Eingeleitet | Needham | Buy |
| 2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
SMMT Stock Gains After Summit Reports Strong Lung Cancer Survival Results — Investors Await Q2 Earnings - stocktwits.com
Why Is SMMT Stock Tumbling Today? - stocktwits.com
Summit Therapeutics Inc. (SMMT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Summit Therapeutics plc (SMMT) stock price, news, quote and history - Yahoo Finance UK
Summit Therapeutics Inc. (SMMT) latest stock news and headlines – Yahoo Finance - Yahoo Finance Singapore
Summit Therapeutics Inc. (SMMT) stock price, news, quote and history - Yahoo Finance Australia
Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock By Investing.com - Investing.com Nigeria
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESM - BioSpace
Barclays Keeps Their Hold Rating on Summit Therapeutics (SMMT) - The Globe and Mail
Summit Therapeutics (SMMT): Time To Take A Look Ahead Of The FDA Decision - RTTNews
Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Maintains Target Price $18 - Moomoo
Summit Therapeutics Inc. (SMMT) Investor Outlook: A 61.77% Potential Upside Amidst Biotech Innovations - DirectorsTalk Interviews
Summit Therapeutics (SMMT) Shows Promise in Lung Cancer Trial bu - GuruFocus
Summit Therapeutics: It’s Okay Not To Have An Answer (NASDAQ:SMMT) - Seeking Alpha
Ivonescimab vs Pembrolizumab: New Data From HARMONi-2 in Advanced NSCLCSummit Therapeutics - Oncodaily
Is Summit Therapeutics (SMMT) Below Fair Value On New Ivonescimab Survival Data? - finance.yahoo.com
Form 8K Summit Therapeutics PLC For: 15 September By Investing.com - Investing.com UK
SMMT News | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Form 8K Summit Therapeutics PLC For: 14 September By Investing.com - Investing.com UK
Why Is Summit Therapeutics Stock Gaining Monday? - Benzinga
Summit Therapeutics (SMMT) Shows Promising Trial Results but Faces Valuation Challenges - GuruFocus
Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial (SMMT:NASDAQ) - Seeking Alpha
Summit Therapeutics (SMMT) Gains Attention as Phase III Trial Da - GuruFocus
Citi Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Jefferies upgrades Summit Therapeutics stock rating on trial outlook By Investing.com - Investing.com South Africa
Summit Therapeutics Shares Rise After Upgrade From Jefferies - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Summit Therapeutics shares gain after Jefferies upgrades stock to Buy - Yahoo Finance
Summit Therapeutics stock surges on Jefferies upgrade to buy By Investing.com - Investing.com Canada
Jefferies Upgrades Summit Therapeutics to Buy From Hold, Adjusts Price Target to $25 From $15 - Yahoo Finance
UBS Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $33 - Moomoo
Summit Therapeutics Inc. (SMMT) Investor Outlook: Exploring A Potential 61.45% Upside - DirectorsTalk Interviews
Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress - Yahoo Finance
Why Is SMMT Stock Surging Over 10% In Overnight Trading? - Stocktwits
Ivonescimab Demonstrates an Overall Survival Benefit in Advanced NSCLCSummit Therapeutics - Oncodaily
Why Summit Therapeutics (SMMT) Is Up 19.5% After New Ivonescimab Phase III Survival DataAnd What's Next - simplywall.st
Summit Therapeutics: The High Stakes Of Translating China Clinical Data To The U.S. (SMMT) - Seeking Alpha
Why is Summit Therapeutics stock surging today? By Investing.com - Investing.com South Africa
Summit's Ivonescimab Beats Merck's Keytruda on Survival in Chinese Lung Cancer Trial - finance.biggo.com
Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug - Barron's
Why Is Summit Therapeutics Stock Soaring Today?Summit Therapeutics (NASDAQ:SMMT) - Benzinga
Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday - Benzinga
Why is Summit Therapeutics stock surging today? - investing.com
Summit Therapeutics stock rises on positive survival data By Investing.com - Investing.com Nigeria
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):